Posted on

cbd oil paranoia

The difference in experience when using the two cannabinoids comes down to the fact that THC binds directly to the CB1 receptor, and CBD does not bind to any receptor at all. The relationship between THC and the CB1 receptor is robust. On the other hand, CBD is thought to activate and inhibit endocannabinoid receptor activity superficially, without a similarly stable connection.

The research on this topic doesn’t end there. An increasing body of evidence suggests cannabinoids do, in fact, offer relief from PTSD symptoms.

Researchers compared the expression of anxiety between two groups of lab rats when exposed to a predator threat. One group received CBD, and the other received nothing. The experiment was designed to stimulate the experience of humans with Post Traumatic Stress Disorder to some extent.

Comparing Apples to Oranges

For anyone unfamiliar with using CBD, the experience is altogether different from that of using THC. While THC alters perception, inhibits memory function, and triggers episodes of paranoia, CBD does not. Most people report that taking CBD, even in high doses, feels like nothing at all. A gentle feeling of relaxation (without sedation) is sometimes reported, but there is absolutely no associated high.

But what happens when patients using medical marijuana experience relief from their symptoms, but also experience the paranoia associated with THC? Where do people turn if they want to continue using marijuana as a safe alternative treatment, but struggle through the psychoactive ups and downs of THC heavy strains?

But the research also clearly shows that some people are more susceptible than others to the increased paranoia triggered by ingesting THC. Even in people who tolerate the psychoactive high of THC quite well, when taken in too high a dosage (either on purpose or by accident), it’s common to get altogether too high. While not dangerous, a marijuana ‘overdose’ still is extremely uncomfortable and unsettling.

Cannabidiols’ anti-paranoia potential goes far beyond its usefulness with THC. Many studies link CBD to reduced fear, anxiety, and paranoia when used on its own. Perhaps one of the most powerful demonstrations of its anti-paranoia potential is from a study on lab mice published in 2012.

Community-based studies suggest that cannabis products that are high in Δ 9 -tetrahydrocannabinol (THC) but low in cannabidiol (CBD) are particularly hazardous for mental health. Laboratory-based studies are ideal for clarifying this issue because THC and CBD can be administered in pure form, under controlled conditions. In a between-subjects design, we tested the hypothesis that pre-treatment with CBD inhibited THC-elicited psychosis and cognitive impairment. Healthy participants were randomised to receive oral CBD 600mg (n=22) or placebo (n=26), 210 min ahead of intravenous (IV) THC (1.5 mg). Post-THC, there were lower PANSS positive scores in the CBD group, but this did not reach statistical significance. However, clinically significant positive psychotic symptoms (defined a priori as increases ≥3 points) were less likely in the CBD group compared with the placebo group, odds ratio (OR)=0.22 (χ 2 =4.74, p<0.05). In agreement, post-THC paranoia, as rated with the State Social Paranoia Scale (SSPS), was less in the CBD group compared with the placebo group (t=2.28, p<0.05). Episodic memory, indexed by scores on the Hopkins Verbal Learning Task-revised (HVLT-R), was poorer, relative to baseline, in the placebo pre-treated group (-10.6±18.9%) compared with the CBD group (-0.4%±9.7 %) (t=2.39, p<0.05). These findings support the idea that high-THC/low-CBD cannabis products are associated with increased risks for mental health.